Abstract
To the Editor: Immune checkpoint inhibitors (ICIs) have been associated with the development of multiple cutaneous and/or extracutaneous immune-related adverse events (cirAEs/irAEs) in cancer patients.1,2 Multiple distinct toxicities developing simultaneously or sequentially in the same organ system are particularly common in the skin, given the prevalence of cirAEs and wide range of morphologic subtypes,3,4 but these patterns remain poorly characterized. We thus sought to compare morphologic patterns among patients with single versus multiple cirAEs and examine associations between cirAE features, irAE risk, and survival outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
